Results 141 to 150 of about 28,252 (277)

Photoactivated iridium(III) complexes drive pyroptosis–necroptosis synergy for multi‐network photoimmunotherapy of renal cell carcinoma

open access: yesSmart Molecules, EarlyView.
Photoactivated iridium(III) complexes trigger mitochondrial DNA leakage and Ca²⁺ efflux, simultaneously driving pyroptosis and necroptosis to synergistically enhance immunogenic cell death. This multi‐network cascade promotes dendritic cell maturation and CD8⁺ T cell activation, achieving potent photoimmunotherapy of renal cell carcinoma.
Xin Qin   +16 more
wiley   +1 more source

Peptide‐directed nanovehicles enabling tumor‐selective ROS amplification and antitumor immunity

open access: yesVIEW, EarlyView.
Cancer cells are vulnerable to oxidative stress, yet exploit immune tolerance to escape destruction. In contrast, their metabolic profile is markedly altered to support rapid proliferation, accompanied by elevated production of reactive oxygen species (ROS).
Manuela Calin   +3 more
wiley   +1 more source

Targeting nuclear export and Janus Kinase/Signal Transducer and Activator of Transcription (JAK/STAT) signalling in myelofibrosis: A novel combinatorial strategy that impacts intrinsic and microenvironment‐related pathways

open access: yesBritish Journal of Haematology, EarlyView.
Selinexor targets molecular pathways critical to myelofibrosis (MF) progenitor cell fitness and demonstrates complementary activity with ruxolitinib, supporting its potential as a novel disease‐modifying therapeutic strategy for MF. Summary Myelofibrosis (MF) is a chronic myeloproliferative neoplasm (MPN) characterized by splenomegaly, constitutional ...
Trinayan Kashyap   +7 more
wiley   +1 more source

Integrating novel therapeutic strategies in myeloproliferative neoplasms: Driving disease‐directed progress

open access: yesBritish Journal of Haematology, EarlyView.
Summary Over the past decade, there has been a substantial increase in the diversity and number of therapeutic options for myeloproliferative neoplasms (MPNs). While many remain within the clinical trial arena, the clinician and patient community have seen more approvals reaching the clinic and a rethink on how best we should be approaching these ...
Trung Q. Ngo   +3 more
wiley   +1 more source

Therapeutic potential of natural products in cancer immunotherapy: Advances and challenges

open access: yesBritish Journal of Pharmacology, EarlyView.
This review systematically outlines the mechanisms underlying tumour immunotherapy resistance and elucidates the role of natural products in enhancing therapeutic efficacy as immunomodulatory adjuvants. Abstract Immunotherapy has emerged as a clinically pivotal approach in cancer treatment, but its application remains limited to a small subset of ...
Rao Hu   +6 more
wiley   +1 more source

miR-489 induces immunogenic cell death in breast cancer by targeting LAPTM4B. [PDF]

open access: yesFront Oncol
Gupta G   +5 more
europepmc   +1 more source

To Treat or Not to Treat: Navigating Early‐Stage CLL in the Era of Targeted Therapy

open access: yesEuropean Journal of Haematology, EarlyView.
ABSTRACT Chronic lymphocytic leukemia (CLL) is most frequently diagnosed at early, asymptomatic stages (Rai 0/Binet A), in which a watch‐and‐wait strategy remains the standard of care, based on historical trials demonstrating no overall survival benefit from early treatment.
Enrica Antonia Martino   +16 more
wiley   +1 more source

Calreticulin Type 26 Mutation in Myelofibrosis: A Rare Variant With Diagnostic Challenges. [PDF]

open access: yesJ Clin Lab Anal
Maltese T   +6 more
europepmc   +1 more source

ER proteostasis meets mitochondrial function: contact sites as hubs of communication and therapeutic targets

open access: yesThe FEBS Journal, EarlyView.
Proteostasis ensures proper protein folding, modification, and degradation, while its impairment triggers ER stress. Chronic ER stress and maladaptive UPR via the CHOP–ERO1 axis remodel ERMCs, altering calcium signaling and mitochondrial metabolism.
Giorgia Maria Renna   +5 more
wiley   +1 more source

Home - About - Disclaimer - Privacy